Drugs / Homosalate
Homosalate
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03582215 | Jul 2018 → Feb 2019 | skin sensitivity to sun | Food and Drug Administration (FDA) | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT01001975 | Jul → Aug 2009 | skin sensitivity to sun | Bayer | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00530387 | Jul 2008 → Jul 2011 | photoallergic dermatitis | NHS Tayside | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Homosalate | “Ingredients: 3% Avobenzone; 6% Oxybenzone; 2.35% Octocrylene; 15% Homosalate; 5% Octisalate” NCT03582215 ↗ |
| Known as | Eusolex | ChEMBL registry synonym — accepted as the source's own label CHEMBL1377575 ↗ |
| Known as | Homomenthyl salicylate | ChEMBL registry synonym — accepted as the source's own label CHEMBL1377575 ↗ |
| Known as | Homosalato | ChEMBL registry synonym — accepted as the source's own label CHEMBL1377575 ↗ |
| Known as | NSC-164918 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1377575 ↗ |
| Modality | Small molecule | — CHEMBL1377575 ↗ |